Premium
Moclobemide (Ro 11‐1163) versus tranylcypromine in the treatment of endogenous depression
Author(s) -
Gabelic I.,
Kuhn B.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05334.x
Subject(s) - moclobemide , tranylcypromine , hamilton rating scale for depression , depression (economics) , medicine , endogenous depression , pharmacology , antidepressant , anesthesia , endogeny , psychiatry , mood , monoamine oxidase , chemistry , major depressive disorder , macroeconomics , hippocampus , economics , enzyme , biochemistry
In this study, moclobemide (100–350 mg daily) was compared with tranylcypromine (10–30 mg daily) in 40 patients with endogenous depression. Treatment was randomly allocated and most patients also received benzodiazepines or mild neuroleptics concomitantly. Improvement on the Hamilton Rating Scale for Depression at the end of treatment was 66% for moclobemide and 41% for tranylcypromine patients. There were 3 suspected tyramine reactions in patients on tranylcypromine. Tolerance was considered good or very good for 95% of moclobemide patients, and for 75% of tranylcypromine patients. No clinically relevant changes in laboratory data were attributed to either of the trial drugs. The results clearly favour moclobemide over tranylcypromine for both efficacy and tolerance in the treatment of endogenous depression.